Generex Biotechnology Creates Scientific Advisory Board to Further the Progression of Its Drug Development Programs

Anticipates Adding Several Industry Leaders in the Fields of Oncology and Metabolic Science in the Coming Weeks.

This content was submitted directly to this website by the supplier.

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has created a scientific advisory board in an effort to further its drug development programs, specifically in the areas of oncology and metabolic diseases. Management of Generex has been in late stage talks with a number of key industry leaders in the pharmaceutical and biotechnology industry to assist the Company in positioning its more later stage drug delivery and vaccine programs for commercialization and to further the advancement of its rich pipeline of metabolic and oncology related programs.

"We believe we are at the cusp of several significant advancements toward the commercial realization for the sciences we have been developing at our Company since our inception. We are confident that now is the time to bring a number of industry leaders together to help to guide our Company down the path to commercial success," stated Anna Gluskin, the Company's President & Chief Executive Officer. "We have been in discussions with some current industry leaders in oncology and metabolic diseases and we look forward to bringing in a group of professionals capable of providing us with the additional experience and insight to help us deliver on the promise of our strong pipeline of life improving drug programs."
Companies in this article
More in Home